Log in to search using one of your social media accounts:

 

07.02.18: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 23, 2018 Category: Pharmaceuticals Source Type: news

Avista continues growth with another acquisition
Durham-based contract development and manufacturing organization Avista Pharma Solutions is starting 2018 with a Scottish acquisition and a new facilities expansion on the heels of significant growth last year. Avista said Tuesday that it has acquired fellow contract services company Solid Form Solutions – located in Edinburgh, Scotland. CEO Pat Walsh says the company is also busy “embarking on another facility expansion in Durham.”  “We’re very active in looking at additional acquisitions,” … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2018 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

Avista continues growth with another acquisition
Durham-based contract development and manufacturing organization Avista Pharma Solutions is starting 2018 with a Scottish acquisition and a new facilities expansion on the heels of significant growth last year. Avista said Tuesday that it has acquired fellow contract services company Solid Form Solutions – located in Edinburgh, Scotland. CEO Pat Walsh says the company is also busy “embarking on another facility expansion in Durham.”  “We’re very active in looking at additional acquisitions,” … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 23, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

New York City sues Big Pharma over the opioid epidemic
The opioid epidemic has kills more than 1,000 people in New York City each year, and the city is suing more than a dozen drug makers for negligence that has cost New York millions. (Source: the Mail online | Health)
Source: the Mail online | Health - January 23, 2018 Category: Consumer Health News Source Type: news

Guess what? Part B drug spending remains stable share of Medicare spending
Did you know that if you look at medicines in the pipeline for previously unmet medical needs, many are new and exciting immunotherapy treatments that are physician administered? That means these innovative medicines will fall under Part B coverage after Food and Drug Administration approval. Between 2006 and 2013, for example, there were 83 new medicines approved that are now covered by Part B, many of which are used to treat cancer or blood diseases. And a report out last year found there aremore than 240 new immuno-oncology treatments in development. (Source: The Catalyst)
Source: The Catalyst - January 23, 2018 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

Boris Johnson faces backlash on demand for NHS Brexit dividend
Tory MPs accuse foreign secretary of ‘transparent leadership bid’ (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 23, 2018 Category: Pharmaceuticals Source Type: news

GSK leads drugmakers’ fight against superbugs
Report says generics manufacturers trailing in battle against antibiotic resistance (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 23, 2018 Category: Pharmaceuticals Source Type: news

NPPA fixes retail price of 5 formulations
The national Pharmaceutical Pricing Authority (NPPA) has also revised the ceiling price of Metronidazole injection used for treatment of the bacterial infections. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 23, 2018 Category: Pharmaceuticals Source Type: news

Skyhawk Therapeutics Launches With $8 Million in Seed Financing to Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression
The company's founders are leading experts in the development of small molecule therapeutics for RNA-driven disease. Skyhawk's initial pipeline is focused on neurological and cancer indications WALTHAM, Mass., Jan. 23, 2018 -- (Healthcare Sales & Market... Biopharmaceuticals, Venture Capital, Personnel Skyhawk Therapeutics, RNA expression (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2018 Category: Pharmaceuticals Source Type: news

TECHLAB Receives FDA 510(k) Clearance To Market CAMPYLOBACTER QUIK CHEK(TM) and CAMPYLOBACTER CHEK(TM) Tests
Tests Help Clinicians Diagnose Diarrhea Caused by Campylobacter Bacteria BLACKSBURG, Va., Jan. 23, 2018 -- (Healthcare Sales & Marketing Network) -- TECHLAB, Inc., a leading developer and manufacturer of rapid non-invasive diagnostic tests for gastroin... Diagnostics, Gastroenterology, Product Launch TECHLAB, CAMPYLOBACTER, QUIK CHEK (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2018 Category: Pharmaceuticals Source Type: news

May and Hammond reject Johnson’s call for £5bn health booster
Chancellor rebukes foreign secretary for intervention outside his department (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 23, 2018 Category: Pharmaceuticals Source Type: news

Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M & A
Celgene is acquiring Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. The author analyzes the price per share and returns over each of the biotech's funding rounds. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 23, 2018 Category: Pharmaceuticals Authors: Bruce Booth, Contributor Tags: NASDAQ:JUNO Source Type: news

About Those Soaring Pharma Profits
Let ’s not attack the industry with accusations of obscene profits. It is not true. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 23, 2018 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE NYSE:BMY NYSE:MRK NYSE:AZN NYSE:LLY Source Type: news

Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences
CAMBRIDGE, Mass., Jan. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological diseas... Biopharmaceuticals, Neurology, Personnel Disarm Therapeutics, axonal degeneration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2018 Category: Pharmaceuticals Source Type: news

Louisville company sends SAG Awards host Kristen Bell a special message
A Louisville company has a connection with Kristen Bell, the host of this week's Screen Actors Guild Awards program. The connection goes back to September, as Hurricane Irma was approaching Florida. Louisville-based Atria Senior Living Inc. relocated more than 600 residents (and 50 pets) from communities across Florida to the Walt Disney World Dolphin and Swan Resort. The company has a sheltering agreement with the resort. Kristen Bell also was at the resort, and she spent time with the Atria… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2018 Category: Pharmaceuticals Authors: Carolyn Tribble Greer Source Type: news

Johnson & Johnson Reports 2017 Fourth-Quarter Results:
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 23, 2018 Category: Pharmaceuticals Source Type: news

Sarasota economic powerhouse boosts revenue, operating income
Increased surgery volume was a major factor behind jumps in operating revenue and operating income for Sarasota County Public Hospital District in fiscal year 2017. But a dip in investments pulled down total income for the year ended Sept. 30 for the district, which operates Sarasota Memorial Health Care System. The system, with a staff of 5,600 and a $394 million total payroll, is among the region’s largest employers, and its $731 million in total operati ng expenses help support a variety of… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2018 Category: Pharmaceuticals Authors: Margie Manning Source Type: news

All 3 Columbus health systems have adopted Affordable Care Act's Medicare savings program
All three Columbus health systems have now joined a five-year-old Affordable Care Act initiative to split the government's savings with hospitals that lower the cost of Medicare. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2018 Category: Pharmaceuticals Authors: Carrie Ghose Source Type: news

Cambridge's Idera plans eventual move out of state after merger with BioCryst
On Monday, Cambridge-based Idera Pharmaceuticals announced plans to merge with BioCryst Pharmaceuticals, based in Durham, North Carolina, with the resulting company to be based in Exton, Pennsylvania. The combined company – to be renamed upon the merger’s closing – will be headquartered in Exton, with a consolidated research center slated for Birmingham, Alabama.  As part of the all-stock deal, a spokesman for Idera (Nasdaq: IDRA) said Monday that eventually that company's current Cambr idge… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2018 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

New York Puts Up $100 Million, Asks For Plans For A Biotech Hub
New York City's government is today asking for proposals on how to use $100 million in funds and city land to create a " life sciences hub " with the goal of making the city competitive with Boston and San Francisco as a place to start biotechnology companies. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 23, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news

Cells of 3 advanced cancers die with drug-like compounds that reverse chemo failure
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers - ovarian, prostate and breast. The molecules were first discovered computationally via high-performance supercomputing. Now their effectiveness against specific cancers has been confirmed via wet-lab experiments, said biochemistry professors Pia Vogel and John G. Wise, who led the study. (Source: World Pharma News)
Source: World Pharma News - January 23, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Earnings Preview: What To Expect From Biogen On Thursday
Biogen is expected to report earnings of $5.44/share on $3.06 billion in revenue. Meanwhile, the so-called Whisper number is $5.55. The Whisper number is the Street's unofficial view on earnings. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 23, 2018 Category: Pharmaceuticals Authors: Adam Sarhan, Contributor Tags: NASDAQ:BIIB NASDAQ:REGN NASDAQ:AMGN NASDAQ:CELG NASDAQ:GILD Source Type: news

Carlyle Group leads race for 15 per cent in Mankind Pharmaceuticals
The company, which is the maker of leading brands such as Manforce condoms, PregaNews and Unwanted 72, has presence in about 22 countries across Southeast Asia, Africa and the Middle East, according to the company ’s website. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 23, 2018 Category: Pharmaceuticals Source Type: news

Biotech M & A In 2018: A Tsunami Or A Ripple?
A pair of big deals announced by Celgene and Sanofi is a reminder that early predictions are that 2018 will see a resurgence in biotech M&A, thanks in part to President Trump ’s tax reform. But pegging the winners is no easy feat. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 23, 2018 Category: Pharmaceuticals Authors: Johanna Bennett, Contributor Tags: NASDAQ:IBB NASDAQ:CELG NASDAQ:JUNO Source Type: news

How Juno's CEO broke the $9 billion takeover news to employees, vendors and founders
Juno Therapeutics Inc. and CEO Hans Bishop emailed employees, founders and vendors Monday morning to let them know of the company's $9 billion deal to sell to Celgene Corp. "For many of us this is a surprising development, and I am sure comes with some mixed emotions," he told employees. "We all will have many questions – some that we have answers to and some that we do not." Celgene increased its investment in Seattle-based Juno last year after the failure of i ts flagship drug trail. Juno… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2018 Category: Pharmaceuticals Authors: Casey Coombs Source Type: news

New Morning-After Hangover Herbal Remedy Raises The Bar On Indiegogo
Pharmacist creates morning after relief after a night of drinking(PRWeb January 23, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15092210.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 23, 2018 Category: Pharmaceuticals Source Type: news

Almac Group Implements Salesforce Service Cloud to Enhance Client and...
Salesforce Service Cloud, a best-in-class customer service software platform enables real-time support for Almac clients and clinical site users.(PRWeb January 23, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15115427.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 23, 2018 Category: Pharmaceuticals Source Type: news

Morae Global Announces Executive Promotions
Teju Deshpande and John O’Connor were named Managing Directors, and Samir Ismayilov and Meredith Wells were named Senior Directors(PRWeb January 23, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15119533.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 23, 2018 Category: Pharmaceuticals Source Type: news

Scientist.com CTO Joins Forbes Technology Council of Industry Thought...
Chris Petersen Joins Invitation-Only Community of World-Class CIOs, CTOs and Technology Executives.(PRWeb January 23, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15118015.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 23, 2018 Category: Pharmaceuticals Source Type: news

Forte Named a CenterWatch Top Innovator for 2018
Forte recognized by The CenterWatch Monthly as one of 20 Top Innovators for 2018 for its Protocol Calendar Exchange.(PRWeb January 23, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15123724.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 23, 2018 Category: Pharmaceuticals Source Type: news

FDA Executives, Editor in Chief at IRAI, FBI Official & Industry...
ComplianceOnline Medical Device Summit 2018 will bring together current and former FDA office bearers, FBI officials, regulators, industry veterans and policy influencers as well as several...(PRWeb January 23, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15121025.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 23, 2018 Category: Pharmaceuticals Source Type: news

DiabetesSisters Welcomes New Board Members Rita Kalyani, MD and Frank...
DiabetesSisters is pleased to announce the election of two highly esteemed physicians, Rita Kalyani, MD and Frank Lavernia, MD, to its Board of Directors, effective January 19, 2018.(PRWeb January 23, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15117105.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 23, 2018 Category: Pharmaceuticals Source Type: news

Here's why Measure 101 may pass on Tuesday
Ballots aren ’t due until 8 p.m. Tuesday, but already there may be some indications that access to health will trump anti-tax sentiment and voters will pass Measure 101, several political observers predicted.  As of today, 747,525 ballots have been cast, or 28 percent of eligible voters, according to the Sec retary of State's running tally. Measure 101 asks voters to ratify a package of taxes on hospitals and health insurance companies to close a $320 million Medicaid budget shortfall and fund… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 22, 2018 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

Pharmacy benefits company to relocate to Sacramento, add dozens of jobs
RxTE Health was spun off from Safeway Inc. in its merger with the Albertsons supermarket chain. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 22, 2018 Category: Pharmaceuticals Authors: Scott Rodd Source Type: news

Heat latest Triangle biopharma to execute reverse stock split
On the heels of Argos Therapeutics (Nasdaq: ARGS) executing a one-for-twenty reverse stock split, another Durham-based biopharmaceutical company Heat Biologics (Nasdaq: HTBX) has undertaken a one-for-ten reverse stock split of its own. Heat’s reverse stock split – as in the case of Argos – comes after shares of the company had remained below $1 for the better part of 2017 and the beginning of 2018.  In a filing with the SEC, Heat stated that it “has until March 12, 2018 to regain compliance… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 22, 2018 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

Denver Health eating-disorders center doubles its number of beds
Denver Health ’s Acute Center for Eating Disorders has doubled its number of beds — an expansion that leaders say is a reaction to an increase in the number of patients needing its services. The 10-year-old center that began with two inpatient beds now is home to 30 around-the-clock beds designed to treat me n and women who have the most severe cases of eating disorders. That includes patients from around the world, some of whom are flown in on air ambulances of partner Angel Med Flight if commercial… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 22, 2018 Category: Pharmaceuticals Authors: Ed Sealover Source Type: news

Will Austin lose biopharma HQ to Connecticut? It depends on who you ask
Vermillion has experienced a bumpy ride on the Nasdaq in 15-plus years. In 2015, it leased office and lab space in Connecticut, where its CEO and CFO work. Now there are conflicting accounts of whether it plans to shift its headquarters there. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 22, 2018 Category: Pharmaceuticals Authors: Mike Cronin Source Type: news

Amgen Reports Aimovig ™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments
LIBERTY is the First Migraine Prevention Trial of its Kind Conducted Specifically in Patients Who Have Tried Multiple Therapies Without Success, and are in Need of Additional Treatment Options The Trial Met its Primary Endpoint of Percentage of Patients on Aimovig Achieving at Least a 50 Percent Reduction of Migraine Days Versus Placebo, and all Secondary Endpoints Results Add to the Consistent Efficacy, Safety and Tolerability Profile of Aimovig Across the Spectrum of Migraine, Even in More Difficult to Treat Patients THOUSAND OAKS, Calif., Jan. 22, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced po...
Source: Amgen News Release - January 22, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Big Pharma makes strongest start to M&A for a decade
US tax overhaul spurs near-$30bn spree but some warn of bubble amid high valuations (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 22, 2018 Category: Pharmaceuticals Source Type: news

Johnson and Johnson Vision Expands Parameter Offering for 1-DAY ACUVUE(R) MOIST Brand Contact Lenses for ASTIGMATISM
Nearly half of vision-corrected patients has astigmatism in at least one eye,(1) and full correction can provide improved visual quality of life(2) JACKSONVILLE, Fla., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Vision ... Devices, Ophthalmology, Product Launch Johnson & Johnson, Johnson & Johnson Vision, ACUVUE MOIST (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology
SAN FRANCISCO, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced the appointment of Hicham Alaoui, Ph.D., as Senior Vice President of Discov... Biopharmaceuticals, Personnel Symic Bio, matrix-targeting biotherapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Hologic's Cynosure Division Launches TempSure(TM) Envi
Superior Radiofrequency Treatment Minimizes Fine Facial Lines and Wrinkles, Tightens Skin Through Soft Tissue Coagulation, and Improves the Appearance of Cellulite MARLBOROUGH, Mass., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Hologic's... Devices, Dermatology, Product Launch Hologic, TempSure (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Elanco Animal Health Announces U.S. Food and Drug Administration (FDA) Approval of Credelio(R) (lotilaner) to Treat and Protect Against Ticks and Fleas
New monthly oral tick and flea treatment offers easy dosing, efficacy in as little as four hours, all month long GREENFIELD, Ind., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Today, Elanco Animal Health, a division of Eli Lilly and Comp... Biopharmaceuticals, FDA Elanco Animal Health, Eli Lilly, Credelio, lotilaner (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

AVACEN Medical Device for Autistic Spectrum Disorder Behavior Management Launched in Hong Kong
50% Discounted Launch Price Offered SAN DIEGO, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- AVACEN Medical, Inc. (AVACEN) announced that it is launching sales of its AVACEN 100, an FDA-cleared and CE marked, class II dry-heat therapy medi... Devices, Product Launch AVACEN Medical, AVACEN 100, autistic spectrum disorder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Court dismisses whistleblower suit against Express Scripts unit
A federal appeals court has upheld the dismissal of a whistleblower lawsuit filed against Medco Health Solutions, a specialty pharmacy acquired by Express Scripts Holding Co. The suit alleged Medco paid kickbacks disguised as charitable donations in exchange for patient referrals, Reuters reports. The Third U.S. Circuit Court of Appeals in Philadelphia upheld the dismissal of the suit, saying the whistleblower, a former employee of Medco affiliate Accredo Health Group, did not show a sufficient… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 22, 2018 Category: Pharmaceuticals Authors: Angela Mueller Source Type: news

Fred Colen Appointed Chief Executive Officer of Neovasc Inc.
NCOUVER, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its boa... Devices, Interventional, Cardiology, Personnel Neovasc , Reducer, Tiara, transcatheter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
TARRYTOWN, N.Y., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization... Biopharmaceuticals, Dermatology, Regulatory Regeneron Pharmaceuticals, Sanofi, DUPIXENT, dupilumab, atopic dermatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Titan In Discussions With Braeburn Regarding U.S. Probuphine(R) Commercialization
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-ter... Biopharmaceuticals Titan Pharmaceuticals, Braeburn Pharmaceuticals, ProNeura, Probuphine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

With new Cary HQ underway, Chiesi USA eyes growth
With construction of its new headquarters overlooking Symphony Lake underway, Cary-based pharmaceutical company Chiesi USA has its sights set on more growth in 2018. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 22, 2018 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
TOKYO and SAN DIEGO, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Vical Incorporated (NASDAQ: VICL) announced today that ASP0113, an investigat... Biopharmaceuticals Astellas Pharma, Vical , cytomegalovirus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news